JP2023510258A - 安定なシクロデキストリン不含カルフィルゾミブ処方物 - Google Patents

安定なシクロデキストリン不含カルフィルゾミブ処方物 Download PDF

Info

Publication number
JP2023510258A
JP2023510258A JP2022541814A JP2022541814A JP2023510258A JP 2023510258 A JP2023510258 A JP 2023510258A JP 2022541814 A JP2022541814 A JP 2022541814A JP 2022541814 A JP2022541814 A JP 2022541814A JP 2023510258 A JP2023510258 A JP 2023510258A
Authority
JP
Japan
Prior art keywords
cyclodextrin
free
solution
pharmaceutical composition
carfilzomib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022541814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510258A5 (https=
JPWO2021142360A5 (https=
Inventor
カクー，サバハ
ムナイム，カヘラ
カラハン，ウィリアム・ジェイ
テラン，アロナ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2023510258A publication Critical patent/JP2023510258A/ja
Publication of JP2023510258A5 publication Critical patent/JP2023510258A5/ja
Publication of JPWO2021142360A5 publication Critical patent/JPWO2021142360A5/ja
Priority to JP2025175228A priority Critical patent/JP2026016486A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022541814A 2020-01-10 2021-01-08 安定なシクロデキストリン不含カルフィルゾミブ処方物 Pending JP2023510258A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025175228A JP2026016486A (ja) 2020-01-10 2025-10-17 安定なシクロデキストリン不含カルフィルゾミブ処方物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959829P 2020-01-10 2020-01-10
US62/959,829 2020-01-10
PCT/US2021/012826 WO2021142360A1 (en) 2020-01-10 2021-01-08 Stable cyclodextrin free carfilzomib formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025175228A Division JP2026016486A (ja) 2020-01-10 2025-10-17 安定なシクロデキストリン不含カルフィルゾミブ処方物

Publications (3)

Publication Number Publication Date
JP2023510258A true JP2023510258A (ja) 2023-03-13
JP2023510258A5 JP2023510258A5 (https=) 2024-01-16
JPWO2021142360A5 JPWO2021142360A5 (https=) 2024-01-16

Family

ID=74626106

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022541814A Pending JP2023510258A (ja) 2020-01-10 2021-01-08 安定なシクロデキストリン不含カルフィルゾミブ処方物
JP2025175228A Pending JP2026016486A (ja) 2020-01-10 2025-10-17 安定なシクロデキストリン不含カルフィルゾミブ処方物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025175228A Pending JP2026016486A (ja) 2020-01-10 2025-10-17 安定なシクロデキストリン不含カルフィルゾミブ処方物

Country Status (5)

Country Link
US (1) US20250345384A1 (https=)
EP (1) EP4087538A1 (https=)
JP (2) JP2023510258A (https=)
CN (1) CN115279339A (https=)
WO (1) WO2021142360A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516416A (ja) * 2012-05-08 2015-06-11 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドプロテアソーム阻害剤を調合するためのシクロデキストリン錯体形成法
WO2016116882A2 (en) * 2015-01-23 2016-07-28 Leiutis Pharmaceuticals Pvt Ltd Novel compositions of carfilzomib
JP2016534060A (ja) * 2013-10-22 2016-11-04 メダック ゲゼルシャフト フィア クリニッシェ スペツィアルプレパラーテ ミット ベシュレンクタ ハフトゥンク ある含有量のマイトマイシンｃを有する凍結乾燥医薬組成物を製造する方法
JP2017537974A (ja) * 2014-10-30 2017-12-21 ビッグ ディーエヌエイ リミテッドＢｉｇ Ｄｎａ Ｌｔｄ 併用療法
JP2019519530A (ja) * 2016-05-24 2019-07-11 アムジエン・インコーポレーテツド ペグ化されたカルフィルゾミブ化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
TWI674262B (zh) * 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
EP2914296B2 (en) * 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015198257A1 (en) * 2014-06-26 2015-12-30 Intas Pharmaceuticals Ltd. Stable carfilzomib injection

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516416A (ja) * 2012-05-08 2015-06-11 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドプロテアソーム阻害剤を調合するためのシクロデキストリン錯体形成法
JP2016534060A (ja) * 2013-10-22 2016-11-04 メダック ゲゼルシャフト フィア クリニッシェ スペツィアルプレパラーテ ミット ベシュレンクタ ハフトゥンク ある含有量のマイトマイシンｃを有する凍結乾燥医薬組成物を製造する方法
JP2017537974A (ja) * 2014-10-30 2017-12-21 ビッグ ディーエヌエイ リミテッドＢｉｇ Ｄｎａ Ｌｔｄ 併用療法
WO2016116882A2 (en) * 2015-01-23 2016-07-28 Leiutis Pharmaceuticals Pvt Ltd Novel compositions of carfilzomib
JP2019519530A (ja) * 2016-05-24 2019-07-11 アムジエン・インコーポレーテツド ペグ化されたカルフィルゾミブ化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARDIOVASC TOXICOL, vol. 17, JPN6024047221, 2017, pages 58 - 66, ISSN: 0005469069 *
J BIOCHEM MOLECULAR TOXICOLOGY, vol. 28, no. 9, JPN6024047222, 2014, pages 400 - 406, ISSN: 0005469068 *
J PHARM SCI, vol. 88, no. 5, JPN6024047220, 1999, pages 501 - 506, ISSN: 0005469070 *

Also Published As

Publication number Publication date
WO2021142360A1 (en) 2021-07-15
US20250345384A1 (en) 2025-11-13
EP4087538A1 (en) 2022-11-16
JP2026016486A (ja) 2026-02-03
CN115279339A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
TWI603737B (zh) 用於調配胜肽蛋白酶體抑制劑的環糊精錯合法
JP6410264B2 (ja) ペプチドプロテアソーム阻害剤を調合するためのシクロデキストリン錯体形成法
US20260048003A1 (en) Stable cyclodextrin free carfilzomib formulation
JP2023510258A (ja) 安定なシクロデキストリン不含カルフィルゾミブ処方物
HK40114672A (en) Cylodextrin complexation methods for formulating peptide proteasome inhibitors
HK1191237B (en) Cylodextrin complexation methods for formulating peptide proteasome inhibitors
HK1191237A (en) Cylodextrin complexation methods for formulating peptide proteasome inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240105

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250617